MDCX vs. NVS

Last updated Jun 23, 2026

MDCX (Medicus Pharma Ltd) and NVS (Novartis AG) are both stocks. Both are in the Healthcare sector — MDCX in Biotechnology, NVS in Drug Manufacturers - General. Over the past year, MDCX returned -81.97% vs 32.56% for NVS. At a 0.08 correlation, their price movements are largely independent.

Performance

MDCX vs. NVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Medicus Pharma Ltd (MDCX) and Novartis AG (NVS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MDCX achieves a -70.65% return, which is significantly lower than NVS's 11.31% return.

MDCX

• 1D: -1.86%
• 1M: 49.67%
• YTD: -70.65%
• 6M: -71.22%
• 1Y: -81.97%
• 3Y*: —
• 5Y*: —
• 10Y*: —

NVS

• 1D: 1.26%
• 1M: -2.03%
• YTD: 11.31%
• 6M: 12.12%
• 1Y: 32.56%
• 3Y*: 17.94%
• 5Y*: 14.22%
• 10Y*: 10.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

MDCX vs. NVS - Yearly Performance Comparison

	2026 (YTD)	2025	2024
MDCX Medicus Pharma Ltd	-70.65%	-37.04%	-21.61%
NVS Novartis AG	11.31%	46.95%	-6.31%

Correlation

The correlation between MDCX and NVS is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.09
Correlation (All Time) Calculated using the full available price history since Nov 14, 2024	0.08

Fundamentals

EPS MDCX : -$1.93 NVS : $6.99
Total Revenue (TTM) MDCX : $0.00 NVS : $56.05B
Gross Profit (TTM) MDCX : $0.00 NVS : $42.19B
EBITDA (TTM) MDCX : -$36.18M NVS : $22.40B

Return for Risk

MDCX vs. NVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDCX

MDCX Risk / Return Rank: 12
MDCX Sharpe Ratio Rank: 14
MDCX Sortino Ratio Rank: 14
MDCX Omega Ratio Rank: 14
MDCX Calmar Ratio Rank: 7
MDCX Martin Ratio Rank: 9

NVS

NVS Risk / Return Rank: 80
NVS Sharpe Ratio Rank: 83
NVS Sortino Ratio Rank: 79
NVS Omega Ratio Rank: 77
NVS Calmar Ratio Rank: 81
NVS Martin Ratio Rank: 80

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDCX vs. NVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Medicus Pharma Ltd (MDCX) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	MDCX	NVS	Difference
Sharpe ratio: Return per unit of total volatility	-0.65	1.56	-2.21
Sortino ratio: Return per unit of downside risk	-0.88	2.19	-3.07
Omega ratio: Gain probability vs. loss probability	0.88	1.27	-0.39
Calmar ratio: Return relative to maximum drawdown	-0.89	2.59	-3.48
Martin ratio: Return relative to average drawdown	-1.37	6.11	-7.48

MDCX vs. NVS - Sharpe Ratio Comparison

The current MDCX Sharpe Ratio is -0.65, which is lower than the NVS Sharpe Ratio of 1.56. The chart below compares the historical Sharpe Ratios of MDCX and NVS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

MDCX vs. NVS - Drawdown Comparison

The maximum MDCX drawdown since its inception was -96.47%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for MDCX and NVS.

Drawdown Indicators

	MDCX	NVS	Difference
Max Drawdown Largest peak-to-trough decline	-96.47%	-42.10%	-54.37%
Max Drawdown (1Y) Largest decline over 1 year	-91.91%	-12.65%	-79.26%
Max Drawdown (3Y) Largest decline over 3 years	—	-19.95%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-20.42%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-26.03%	—
Current Drawdown Current decline from peak	-94.23%	-8.99%	-85.24%
Average Drawdown Average peak-to-trough decline	-57.66%	-10.92%	-46.74%
Ulcer Index Depth and duration of drawdowns from previous peaks	59.85%	5.34%	+54.51%

Volatility

MDCX vs. NVS - Volatility Comparison

Medicus Pharma Ltd (MDCX) has a higher volatility of 35.89% compared to Novartis AG (NVS) at 7.67%. This indicates that MDCX's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MDCX	NVS	Difference
Volatility (1M) Calculated over the trailing 1-month period	35.89%	7.67%	+28.22%
Volatility (6M) Calculated over the trailing 6-month period	119.19%	15.16%	+104.03%
Volatility (1Y) Calculated over the trailing 1-year period	126.68%	21.05%	+105.63%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	131.88%	18.94%	+112.94%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	131.88%	19.66%	+112.22%

Dividends

MDCX vs. NVS - Dividend Comparison

MDCX has not paid dividends to shareholders, while NVS's dividend yield for the trailing twelve months is around 3.20%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MDCX Medicus Pharma Ltd	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVS Novartis AG	3.20%	2.90%	3.84%	3.44%	3.70%	3.86%	3.22%	3.03%	3.47%	3.24%	3.73%	3.10%

Financials

Frequently Asked Questions

Can I hold both MDCX and NVS in my portfolio?

MDCX and NVS have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MDCX or NVS?

MDCX has higher volatility (35.89%) compared to NVS (7.67%). In terms of maximum drawdown, MDCX dropped -96.47% vs NVS's -42.10%.

Which has better risk-adjusted returns?

NVS currently has the higher Sharpe Ratio (1.56 vs -0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.